CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Myrexis Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Myrexis Inc
600 Fifth Avenue, 2nd Floor
Phone: (801) 214-7800p:801 214-7800 NEW YORK, NY  10020  United States Ticker: MYRXMYRX

This company ceased filing statements with the SEC on 7/31/2013.

Business Summary
Myrexi, Inc. is a development-stage company. The Company was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The Company determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The Company operates in pharmaceutical development and related research activities. The Company’s revenues were derived from research performed in the United States and, all of the Company’s long-lived assets are located in the United States.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20136/30/2013YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Chief Financial Officer, Director Jonathan M.Couchman 45 3/1/2013 1/22/2013
Treasurer, Secretary AndreaKendell 40 3/1/2013 9/6/2011
Independent Director Michael C.Pearce 51 2/13/2013 2/13/2013
Independent Director Steven D.Scheiwe 60 2/13/2013 2/13/2013

Business Names
Business Name
Myriad Pharmaceuticals Inc
Myriad Pharmaceuticals, Inc.
MYRX

General Information
Number of Employees: 1 (As of 6/30/2013)
Outstanding Shares: 34,479,051 (As of 7/12/2013)
Shareholders: 8,435
Stock Exchange: OTC
Federal Tax Id: 263996918
Fax Number: (302) 645-1280


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023